Table 1.
Demographic and clinical features of the patients studied
| APS | SLE | |
| (n = 18) | (n = 10) | |
| Females/Males | 15/3 | 9/1 |
| Age in years | ||
| Mean (range) | 38.4 (28–68) | 36.9 (18–59) |
| Disease duration in months | ||
| Mean (range) | 121 (1–322) | 119 (12–300) |
| Vascular thrombosis | ||
| Venous thrombosis (percentage) | 14/18 (77.7) | 0 |
| Arterial thrombosis (percentage) | 8/18 (44.4) | 0 |
| Recurrent thrombosis (percentage) | 4/14 (28.5) | 0 |
| Pregnancy morbidity | ||
| Normal foetus deaths (percentage) | 0 | 0 |
| Premature births (percentage) | 1/18 (5.5) | 0 |
| Spontaneous abortions (percentage) | 9/18 (50) | 0 |
| Serological features | ||
| aCL IgG (percentage) | 18/18 (100) | 10/10 (100) |
| aCL IgM (percentage) | 11/18 (61) | 5/10 (50) |
| Anti-β2-GPI IgG | 18/18 (100) | 10/10 (100) |
| Anti-β2-GPI IgM | ND | ND |
| Lupus anticoagulant activity (percentage)a | 15/18 (83.3) | 5/10 (50) |
aLupus anticoagulant activity was deduced from recent clinical records. aCL, anticardiolipin antibody; APS, antiphospholipid syndrome; β2-GPI, beta2-glycoprotein I; IgG, immunoglobulin G; IgM, immunoglobulin M; ND, not done; SLE, systemic lupus erythematosus.